Newsroom | 5039 results
Sorted by: Latest
-
BrightHeart Announces Voluson™ Solution Store Collaboration to Deliver Expert-Level AI Support Across the Full Prenatal Ultrasound Exam
PARIS--(BUSINESS WIRE)--BrightHeart, a global leader in AI-driven prenatal ultrasound, today announced the availability of its B-Right AI Platform through GE HealthCare’s Voluson™ Solution Store, bringing advanced AI support directly into routine prenatal care. The addition of this AI platform to the Voluson Solution store is poised to improve early detection of congenital defects, reduce diagnostic uncertainty, and ultimately support better outcomes for clinicians, expectant parents and their...
-
RapidAI Highlights Research Depth and Industry Leadership at ISC 2026 With 28 Clinical Abstracts
SAN MATEO, Calif.--(BUSINESS WIRE)--RapidAI, the pioneer of deep clinical AI and global leader in enterprise imaging, today announced details of 28 scientific abstracts accepted at the International Stroke Conference (ISC) 2026, held February 4-6, at the Ernest N. Morial Convention Center in New Orleans. The abstracts span aneurysm monitoring, ischemic stroke detection, advanced imaging visualization, and radiology workflow optimization. Findings reflect the impact of deep clinical AI delivered...
-
Vizient Opens Applications for 2026 Innovative Technology Exchange
IRVING, Texas--(BUSINESS WIRE)--The 2026 Innovative Technology Exchange will take place in September in Las Vegas during the Vizient Connections Summit. Deadline to apply is April 17...
-
Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
MELBOURNE, Australia--(BUSINESS WIRE)--Imagion Biosystems, Ltd. announced that the company has lodged an IND application with the FDA for its MagSense® targeted imaging agent....
-
QT Imaging Announces Presentation at SPIE Medical Imaging 2026
NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (NASDAQ: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, is pleased to announce that its Chief Science Officer, Bilal Malik, Ph.D., will present at the prestigious International Society for Optics & Photonics (“SPIE”) Medical Imaging meeting taking place in Vancouver, BC, Canada, from February 15–19, 2026. SPIE Me...
-
Butterfly Network to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer...
-
Vizient: Pharmacy Inflation Slows While IT, Construction and Facilities Accelerate
IRVING, Texas--(BUSINESS WIRE)--The Winter Spend Management Outlook projects a 2.78% overall increase in healthcare supply chain prices....
-
ICUS Announces Handy CEUS Coding and Payment Chart, Reflecting Doubled Reimbursement
CHICAGO--(BUSINESS WIRE)--The International Contrast Ultrasound Society (ICUS) today announced a handy new chart that may be used to guide coding and payment for contrast enhanced ultrasound (CEUS) for cardiac and non-cardiac applications – including a new code that doubled reimbursement for certain CEUS scans effective January 1, 2026. The new ICUS coding and payment chart is found on the ICUS website (www.ICUS-Society.org) and is easily accessed on smart phones through the free ICUS mobile ap...
-
Breast Cancer 2026 Progress Outlook: New Research Discoveries and Opportunities
DALLAS--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, today issued its 2026 Breast Cancer Progress Outlook. New data shows the U.S. breast cancer death rate has declined 44% between its peak in 1989 and 2023 — averting an estimated 546,000 deaths due largely to advances in treatment and earlier detection through screening. Yet breast cancer remains an urgent public health challenge. Incidence of invasive breast cancer has been rising since the mid-2000s, incr...
-
GE HealthCare announces U.S. FDA 510(k) clearance and CE Mark for Allia Moveo and marks first global installation, advancing precision care in the interventional suite
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that Allia™ Moveo has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, bringing next-level mobility and precision to the interventional suite. The latest Allia platform, one of the company’s bold innovations first unveiled at the Radiological Society of North America’s (RSNA) 2025 Annual Meeting, assists clinicians in a wide range of cardiovascular, vascular, non-vascular, interventional and...